Armata Pharmaceuticals Stock Investor Sentiment
| ARMP Stock | USD 2.50 0.03 1.19% |
Slightly above 61% of Armata Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Armata Pharmaceuticals suggests that many traders are alarmed. Armata Pharmaceuticals' investor sentiment overview provides quick insight into current market opportunities from investing in Armata Pharmaceuticals. The current market sentiment, together with Armata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Armata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Armata Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Armata daily returns and investor perception about the current price of Armata Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
Armata |
Armata Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Armata Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Armata Pharmaceuticals that are available to investors today. That information is available publicly through Armata media outlets and privately through word of mouth or via Armata internal channels. However, regardless of the origin, that massive amount of Armata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Armata Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Armata Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Armata Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Armata Pharmaceuticals alpha.
Armata Pharmaceuticals Performance against NYSE Composite
Price Growth (%) |
| Timeline |
1 | ARMP Stock Quote Price and Forecast - CNN | 02/28/2024 |
2 | Armata Pharmaceuticals to Release Earnings on Thursday - MarketBeat | 03/13/2024 |
3 | Acquisition by Birx Deborah of 240000 shares of Armata Pharmaceuticals at 3.38 subject to Rule 16b-3 | 03/14/2024 |
4 | Acquisition by Patti Joseph M of 54343 shares of Armata Pharmaceuticals at 3.38 subject to Rule 16b-3 | 03/18/2024 |
5 | Acquisition by Kramer Robin of 10461 shares of Armata Pharmaceuticals at 2. subject to Rule 16b-3 | 03/19/2024 |
6 | Acquisition by Patrick Todd of 23000 shares of Armata Pharmaceuticals at 3.15 subject to Rule 16b-3 | 03/20/2024 |
7 | Armata Pharmaceuticals Receives Buy Rating from HC Wainwright - MarketBeat | 03/22/2024 |
8 | Armata Pharmaceuticals, Inc. Now Trades Above Golden Cross Time to Buy - Yahoo News Canada | 04/11/2024 |
9 | Short Interest in Armata Pharmaceuticals, Inc. Rises By 6.8 percent - Defense World | 04/16/2024 |
10 | Acquisition by Odysseas Kostas D of 28000 shares of Armata Pharmaceuticals at 4.29 subject to Rule 16b-3 | 04/19/2024 |
11 | Armata Pharmaceuticals to Participate in the Cantor Global Healthcare Conference - The Globe and Mail | 04/24/2024 |
Check out Armata Pharmaceuticals Hype Analysis, Armata Pharmaceuticals Correlation and Armata Pharmaceuticals Performance. To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Complementary Tools for Armata Stock analysis
When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Armata Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Armata Pharmaceuticals. If investors know Armata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Armata Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.91) | Revenue Per Share 0.126 | Quarterly Revenue Growth 0.454 | Return On Assets (0.26) | Return On Equity (34.39) |
The market value of Armata Pharmaceuticals is measured differently than its book value, which is the value of Armata that is recorded on the company's balance sheet. Investors also form their own opinion of Armata Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Armata Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Armata Pharmaceuticals' market value can be influenced by many factors that don't directly affect Armata Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Armata Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Armata Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Armata Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.